Primary chemotherapy with doxorubicin and paclitaxel in patients with early breast cancer: final results of a multicenter phase II study

被引：0
作者：
P. Schmid
J. Krocker
G. Morack
V. Heilmann
J.-U. Blohmer
K. Michniewicz
G. Köhler
T. Schaller-Kranz
K. Possinger
D. Elling
机构：
[1] Humboldt University Berlin,Medizinische Klinik II, Department of Oncology and Hematology, Charité Campus Mitte
[2] Oskar-Ziethen-Krankenhaus,Frauenklinik
[3] Frauenklinik Buch,Klinik für Gynäkologie und Geburtshilfe, Charité Campus Mitte
[4] Universitätsfrauenklinik,Frauenklinik
[5] Humboldt Universität zu Berlin,undefined
[6] Ernst-Moritz-Arndt Universität,undefined
[7] Bristol Myers Squibb,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2004年 / 130卷
关键词：
Primary chemotherapy; Neoadjuvant; Early breast cancer; Paclitaxel; Doxorubicin; Adjuvant treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：657 / 663
页数：6
相关论文
共 50 条
  • [21] Preoperative Carboplatin–Paclitaxel–Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study
    Valentina Guarneri
    Maria Vittoria Dieci
    Giancarlo Bisagni
    Corrado Boni
    Katia Cagossi
    Fabio Puglisi
    Annarita Pecchi
    Federico Piacentini
    PierFranco Conte
    Annals of Surgical Oncology, 2015, 22 : 2881 - 2887
  • [22] A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study
    Philippe A. Cassier
    Sylvie Chabaud
    Véronique Trillet-Lenoir
    Pierre-Yves Peaud
    Jean-Dominique Tigaud
    Hervé Cure
    Hubert Orfeuvre
    Bruno Salles
    Claude Martin
    Jean-Philippe Jacquin
    Cecile Agostini
    Jean-Paul Guastalla
    David Pérol
    Thomas Bachelot
    Breast Cancer Research and Treatment, 2008, 109 : 343 - 350
  • [23] High efficacy of paclitaxel and doxorubicin as first-line therapy in advanced breast cancer: A phase I-II study
    De Lena, M
    Latorre, A
    Calabrese, P
    Catino, A
    Lorusso, V
    Mazzei, A
    Aloe, A
    JOURNAL OF CHEMOTHERAPY, 2000, 12 (04) : 367 - 373
  • [24] A phase II study of paclitaxel/cisplatin combination in patients with metastatic breast cancer refractory to anthracycline-based chemotherapy
    Rosati, G
    Riccardi, F
    Tucci, A
    De Rosa, P
    Pacilio, G
    TUMORI, 2000, 86 (03) : 207 - 210
  • [25] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    J. Salvador
    L. Manso
    J. de la Haba
    A. Jaen
    E. Ciruelos
    M. C. de Villena
    M. Gil
    A. Murias
    A. Galan
    C. Jara
    J. Bayo
    J. M. Baena
    J. Casal
    J. R. Mel
    I. Blancas
    P. Sanchez Rvira
    Clinical and Translational Oncology, 2015, 17 : 160 - 166
  • [26] A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer:: results of the ERASME 3 study
    Cassier, Philippe A.
    Chabaud, Sylvie
    Trillet-Lenoir, Veronique
    Peaud, Pierre-Yves
    Tigaud, Jean-Dominique
    Cure, Herve
    Orfeuvre, Hubert
    Salles, Bruno
    Martin, Claude
    Jacquin, Jean-Philippe
    Agostini, Cecile
    Guastalla, Jean-Paul
    Perol, David
    Bachelot, Thomas
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (02) : 343 - 350
  • [27] Long-term results from a phase II study of paclitaxel combined with doxorubicin in recurrent platinum refractory ovarian cancer
    Tropé, C
    Kristensen, G
    Kisic, J
    Kaern, J
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2001, 22 (03) : 223 - 227
  • [28] A Phase II Trial of Neoadjuvant Chemotherapy with Genexol® (Paclitaxel) and Epirubicin for Locally Advanced Breast Cancer
    Lee, Jinsun
    Kim, Jeryong
    Chang, Eilsung
    Choi, Woonjung
    Lee, Kwangman
    Yoon, Hyunjo
    Jung, Sunghoo
    Park, Minho
    Yoon, Junghan
    Kim, Sungyong
    JOURNAL OF BREAST CANCER, 2014, 17 (04) : 344 - 349
  • [29] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    Salvador, J.
    Manso, L.
    de la Haba, J.
    Jaen, A.
    Ciruelos, E.
    de Villena, M. C.
    Gil, M.
    Murias, A.
    Galan, A.
    Jara, C.
    Bayo, J.
    Baena, J. M.
    Casal, J.
    Mel, J. R.
    Blancas, I.
    Sanchez Rvira, P.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (02) : 160 - 166
  • [30] A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study
    Antolin, Silvia
    Mel, Ramon
    Ramos, Manuel
    Garcia-Palomo, Andres
    Almanza, Concepcion
    de Paz, Laura
    Calvo, Lourdes
    Alvarez, Elena
    Gonzalez, Ana
    Garcia-Mata, Jesus
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2011, 13 (09) : 686 - 691
12345